• Sovaldi

    Drug: Sovaldi (soh-VAHL-dee)

    Summary

    sovaldi
    Sovaldi is a polymerase inhibitor that is taken in combination with ribavirin. It is taken once-a-day with or with or without food. Sovaldi is approved by the Food and Drug Administration (FDA) to treat adults infected with hepatitis C (HCV) genotype 2 and 3. Sovaldi is manufactured by Gilead Sciences Inc. Note: Sovaldi is also approved in combination pegylated interferon to treat genotype 1 and 4. This review will only discuss Sovaldi plus ribavirin to treat genotype 2 and 3.

    Initial FDA Approval: 2013
    The wholesale acquisition cost (WAC) for ...

  • Epclusa

    Drug: Epclusa (ep-KLOO-suh)

    Summary

    ep3
    Epclusa is a combination of two drugs—sofosbuvir, a polymerase inhibitor and velpatasvir, a NS5A inhibitor, combined into one pill, taken once-a-day.Epclusa is taken with or without food. Epclusa is approved by the Food and Drug Administration to treat adults infected with chronic hepatitis C (HCV) genotype 1, 2, 3, 4, 5 and 6.It can be taken with and without ribavirin. Epclusa is manufactured by Gilead Sciences Inc.

    The overall cure rates of Epclusa are up to and over 90%.The wholesale acquisition cost (WAC) for Epclusa is $74,760.00 for a ...

  • Daklinza

    Drug:  Daklinza (dak lin za)

    Summary

    daklinza

    Daklinza is an NS5A inhibitor (daclatasvir) that is approved only in combination with another drug — Sovaldi a polymerase inhibitor (sofosbuvir) — to treat chronic hepatitis C genotype 1 and 3 infections.  It is limited to treated just certain conditions.   It can be taken with and without ribavirin.  Daklinza is manufactured by Bristol-Myers Squibb.  Sovaldi is manufactured by Gilead Sciences Inc.

    The overall cure rates of Daklinza plus sofosbuvir are up to and over 90%.  The wholesale acquisition cost (WAC)  for Daklinza is $64,000 for a 12-week ...